All In MedTech

Device Trial Radar · NCT06934096

Ultrasound of the Spleen Utilizing Low-energy (Diagnostic Level) Insonification.

Effects of Ultrasound Insonification of the Spleen on Platelet Activity and Coagulation Biomarkers in Healthy Human Subjects

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

39

Planned (sponsor's estimate)

Start

Jan 8, 2026

Primary completion

Jun 7, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
Northwell HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
GE Healthcare
First posted
Apr 18, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a three-cohort, randomized, double-blinded , sham-controlled, single-center, early feasibility research trial to determine whether organ-specific biologic effects on platelet activity and coagulation are achievable through selective ultrasound of the spleen utilizing low-energy (diagnostic-level) insonification. * Group 1: Focused insonification at center of the spleen. * Group 2: Prolonged duration insonification at center of the spleen * Group 3: Prolonged duration insonification across the spleen. Participants will receive 30 minutes of sham stimulation in the randomized group that is assigned to them, followed by active stimulation within the same group. Blood biomarkers (local and systemic) will be measured before and at several timepoints after stimulation to measure the molecular and cellular effects of the device

Conditions

  • Hemostasis
  • Blood Biomarkers
  • Ultrasound

Interventions

  • Ultrasound Pulsed Doppler Imaging SystemDevice

    Ultrasound pulsed doppler system accompanied with the abdominal curvilinear probe will be used for the purpose of collecting the data for the endpoints.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine whether diagnostic-level ultrasound to the spleen can modulate systemic blood biomarkers of hemostasisTime frame: 4 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Feinstein Institute for Medical Research

    Manhasset, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.